News and Announcements
OncoSil Medical Appoints Charles Rowland as President
- Published December 15, 2015 1:46PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
15th December 2015, ASX Announcement
OncoSil Medical Limited (ASX: OSL) (OncoSil Medical, the Company) is pleased to announce the appointment of Mr. Charles Rowland as President, OncoSil Medical USA.
Mr. Rowland was previously President of Sirtex Medical US from 2002 to 2006, and is a highly experienced healthcare executive with a successful record of commercialising medical devices and growing medical device companies in the diagnostics, cardiac patient management and liver cancer markets.
In his role with OncoSil Medical Mr. Rowland will be responsible for developing and executing the Company’s US Business plan and will be the Company’s official representative with the US FDA as it works towards US licensure for its lead product candidate, the OncoSilTM localiased radiation treatment for cancer.
To read the full announcement, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
